Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding Definium Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 158 | 2 | 174 | +18 |
| Shares | 49.5M | 19.0K | 41.5M | −7.96M (−16.1%) |
| Value | $281.6M | $108.2K | $288.9M | +$7.36M (+2.6%) |
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (37)
Institutions that held Definium Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (19)
Institutions that held Definium Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Alyeska Investment Group, L.P. | 66,694 | $379.5K |
| Balyasny Asset Management LLC | 26,386 | $150.1K |
| GTS Securities LLC | 21,567 | $122.7K |
| Rafferty Asset Management, LLC | 18,658 | $106.2K |
| Sherbrooke Park Advisers LLC | 13,827 | $78.7K |
| Change Path, LLC | 12,462 | $70.9K |
| Voloridge Investment Management, LLC | 11,198 | $63.7K |
| Blair William & Co | 11,000 | $62.6K |
| Wealth Alliance | 11,000 | $62.6K |
| Jaffetilchin Investment Partners, LLC | 2,389 | $13.6K |
| NBC Securities, Inc. | 600 | $3.00K |
| Albion Financial Group | 132 | $752 |
| Tower View Investment Management & Research LLC | 100 | $569 |
| Capital Performance Advisors LLP | 80 | $455 |
| Arrow Financial Corp | 66 | $376 |
| Westside Investment Management, Inc. | 66 | $376 |
| True Wealth Design, LLC | 19 | $109 |
| SJS Investment Consulting Inc. | 12 | $69 |
| Motco | 10 | $57 |
Not filed for Q4 2024 yet (2)
Institutions that held Definium Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 12,789 | $72.8K |
| PEAK6 Investments LLC | 6,223 | $35.4K |